TORONTO, Sept. 21, 2022 /CNW/ – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce that Leann Taylor, President and COO of KetaMD, Inc. (“KetaMD”), has joined the board of…


Previous articleAlgernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program
Next articleOptimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada